FDA Approves Donor Lung Preservation Device That May Result in More Lung Transplants
Washington, DC - Today, the U.S. Food and Drug Administration approved the XVIVO Perfusion System (XPS) with STEEN Solution, a device for preserving donated lungs that do not initially meet the standard criteria for lung transplantation but may be transplantable if there is more time to observe and evaluate the organ’s function to determine whether the lung is viable for transplantation.
Approximately one in five donated lungs meets the standard criteria for a donor lung and is transplanted into a recipient. In 2012, 1,754 lung transplants were performed in the United States and at the end of that year, 1,616 potential recipients remained on the waiting list.
“This innovative device addresses a critical public health need,” said Christy Foreman, director of the Office of Device Evaluation at the FDA’s Center for Devices and Radiological Health. “With this approval, there may be more lungs available for transplant, which could allow more people with end stage lung disease who have exhausted all other treatment options to be able to receive a lung transplant.”
If additional time is needed to determine if a donated lung meets the standard criteria for lung transplantation, the XPS can be used to warm the donor lungs to near normal body temperature and continuously flush the lung tissue with a sterile fluid solution, called STEEN Solution, which preserves the lungs and removes waste products. The XPS also ventilates the lungs, which oxygenates the cells and makes it possible for the transplant team to examine the lungs’ airways with a bronchoscope. Donor lungs can stay in the machine for up to four hours; during this time the transplant team can examine the lungs and evaluate their function. If after further evaluation the lungs meet certain functionality criteria, and pass the transplant surgeon examination, they are transplanted into a recipient. Continue>
Page | 1 2
Posted in: News Briefs | December 9, 2013